

Curriculum Vitae

Personal details

Name: **JOLANTA MARIA SILLER-MATULA**
Date of birth: 22.03.1981
Place of birth: Nowy Sacz, Poland
Marital status: married to Christian Siller
Children: daughter Isabella and son Lionel
Work address: Medical University of Vienna,
Department of Cardiology,
18-20 Waehringer Guertel
1090 Vienna, Austria
Work Phone: 0043-1 40400-46140
Current Position: Associate Professor
E-mail: jolanta.siller-matula@meduniwien.ac.at
Full academic titel: Assoc.Prof.Priv.Doiz.Dr.med. & Dr.phil.

Habilitation: 05.06.2012; Privatdozent (PD)
"Drug-drug interactions in clopidogrel treatment"

PhD Study: 2006-2011; Graduation: Doctor of philosophy (PhD)
"Establishing experimental models to study thrombin effects *in vivo*", Department of Clinical Pharmacology, Medical University of Vienna

Study of Medicine: 2000-2005; Graduation: Medical Doctor (MD)
2000-2002 Medical University of Warsaw, Poland
2002-2005 Medical University of Vienna, Austria

Education

1987-1996 Primary School, Bogusza and Krolowa Gorna, Poland
1996-2000 High School of Jan Dlugosz, Nowy Sacz, Poland
07.06.2000 Final examination with honors

Clinical training in internal medicine: 2007-2013
Clinical training in cardiology: 2013-ongoing

Stay abroad:

POLAND: Department of Cardiology, Poznan University of Medical Sciences,
01-09. 2017 (position: visiting Professor)
AUSTRALIA: Department of Cardiology, Wollongong, 05-06. 2005 (position: fellow)

Languages: Polish, English, German

Research field:

Clinical research on coagulation system and anticoagulation in cardiovascular medicine; Antiplatelet drugs and anticoagulants in cardiovascular indications with a special focus on interventional cardiology

AWARDS and GRANTS:

- 1) Award for the best Habilitation by the Association for the Promotion of Science and Research (Verein zur Förderung von Wissenschaft und Forschung), 2014
- 2) Award by the Department of Culture of the City of Vienna for an excellent scientific track record in medicine sciences, 2014
- 3) Karl Link Early Career Investigator Award in Thrombosis by the American Heart Association, 2013
- 4) Research Grant founded by Roche, 2012
- 5) Werner Klein Award for "the best translational research paper" by the Austrian Society of Cardiology; "ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion", 2012
- 6) Best Poster Award, "Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study", Eurothrombosis 2012

- 7) Research Grant by the Austrian Society of Cardiology, 2012
- 8) Second prize in the category "best clinical paper" by the Austrian Society of Cardiology; "Phenotyping versus Genotyping for Prediction of Clopidogrel Efficacy and Safety: the PEGASUS-PCI study", 2012
- 9) Dr. Maria Schaumayer Award for the PhD Thesis, 2011
- 10) Science Slam Champion, Vienna 2010
- 11) Travel Award by the Vienna Science and Technology Fund, Euro Science Open Forum, Turin, Italy 2010
- 12) Researcher of the Month, Medical University of Vienna, 2009
- 13) First prize in the category "best clinical paper" by the Austrian Society of Cardiology; "Calcium-channel blockers reduce the antiplatelet effect of clopidogrel", 2009
- 14) Best Poster Award; "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel", Conference of the Society of Thrombosis and Haemostasis, 2009
- 15) Travel Award by the British Council, Euro Science Open Forum, Barcelona 2008
- 16) Travel Award by the Austrian Research Association, Scientific Sessions of the American Heart Association, New Orleans, 2008
- 17) Ebrantil Congress Award, Munich 2008
- 18) Austrian Radio Award and Second Prize of Jury in the FameLab, 2008
- 19) Research Grant, Austrian Nationalbank (Nr. 12565), 2007
- 20) Achievement Award, Medical University of Vienna, 2004
- 21) Research Grant, Medical University of Vienna, 2004
- 22) Achievement Award, Polish Ministry of Health, 2003
- 23) Erasmus Scholarship, Medical University of Vienna, 2003
- 24) Achievement Award, Polish Ministry of Health, 2003
- 25) Best Abstract Award, "The air microflora of swimming pools using different methods of water disinfection", Scientific Conference, Gdansk, Poland, 2002
- 26) Achievement Award, Medical University of Warsaw, 2001
- 27) Second Prize in the Academic Competition in Anatomy *Scapula Aurea*, Medical University of Warsaw, 2001

POSITIONS:

- 1) 2016-ongoing: Nucleus member of the Working Group of Thrombosis of the European Society of Cardiology
- 2) 2014-2016: National Leader of the Working Group "Cardiologists of tomorrow", Austrian Society of Cardiology
- 3) 2012-2014: National Co-Leader of the Working Group "Cardiologists of tomorrow", Austrian Society of Cardiology
- 4) 2012-2016: Member of the Works Committee, Medical University of Vienna
- 5) 2013-ongoing: Member of the Curriculum Committee for Medical Education, Medical University of Vienna
- 6) 2008-ongoing: Nucleus member of the Working Group of Cardiovascular Biology and Thrombosis Research of the Austrian Society of Cardiology

MEMBERSHIP:

- 1) Austrian Society of Cardiology: Working Group "Cardiologists of tomorrow", Working Group of Cardiovascular Biology and Thrombosis Research
- 2) European Society of Cardiology: Working Group on Thrombosis, Acute Cardiovascular Care Association, European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 3) Austrian Association of Internal Medicine

Experience with Clinical Trials: GCP Training: 2006 Berlin, 2007 Vienna, Sub-Investigator since 2006: cardiovascular drugs (phase I, II, III) and vaccination trials (phase I, II, III), Principle Investigator since 2011: antiplatelet agents (phase III and IV).

REVIEWER of: Journal of the American Medical Association; European Heart Journal; British Medical Journal; Circulation; Canadian Medical Association Journal; Journal of Internal Medicine; Heart; American Journal of Cardiology; American Heart Journal; Journal of Thrombosis & Haemostasis; Thrombosis & Haemostasis; Thrombosis Research; Platelets; Hämostaseologie; Plos One; Cardiovascular Diabetology; British Journal of Clinical Pharmacology; Expert Opinion on Drug Safety; Expert Opinion on Pharmacotherapy; International Journal of Clinical Pharmacology and Therapeutics; Biochemical Pharmacology; Current Medical Research and Opinion; American Journal of

Gastroenterology; Journal of Clinical Gastroenterology; Inflammation Research; Vascular Pharmacology; Clinical Pharmacology & Therapeutics

OUTREACH: Paint your PhD 2012; Long night of science, Vienna 2012; Jury in FameLab 2012, Vienna; Haemophilia-feel good day, Vienna 2010; SciComm, Vienna 2010; Science Slam, Vienna 2010; Science Salon, Vienna 2010; Euro Science Open Forum, Turin, 2010; Euro Science Open Forum, Barcelona, 2008; Beautiful Science Networking Event, Istanbul 2008; FameLab, Vienna, 2008

INVITED LECTURES on national and international conferences and scientific meetings:

- 1) "Heart failure subtype and thromboembolic risk in patients with atrial fibrillation", TEAM in Atrial Fibrillation Meeting, Windsor, UK, 2017
- 2) "Switching strategies for P2Y12 receptor inhibitors - practical considerations", 10th International Cardiovascular Research Meeting, Bydgoszcz, Poland, 2017
- 3) "How to read clinical articles: translating data into actual clinical practice", Course in career development, Poznan University of Medical Sciences, Poznan, Poland, 2017
- 4) "Antiplatelet treatment strategies in the acute phase of myocardial infarction", Annual Scientific Meeting of the HCP Hospital, Poznan, Poland 2017
- 5) "Controversy in treatment with antithrombotic agents", Scientific Meeting of the Poznan Section of the Polish Society of Cardiology, Poznan, Poland, 2017
- 6) "Antiplatelet treatment in the prehospital phase for an acute coronary syndrome", Meeting for the emergency medical teams, Poznan, Poland, 2017
- 7) "Platelet reactivity testing – is there a clinical relevance?", 21st Congress of the European Haematology Association, Copenhagen, Denmark, 2016
- 8) "Controversy of antiplatelet therapies?" Autumn cardiology meeting, Poznan, Poland 2016
- 9) "Platelet inhibitors: indications, characteristics, platelet function testing", Intensive course in haemostaseology, Vienna, Austria, 2016
- 10) „Cangrelor - Replacement for the GPIIb/IIIa Inhibitors?", Cardiology Live Conference, Vienna, Austria, 2016
- 11) "NSTE-ACS: which antiplatelet drug for whom?", Conference of the Austrian Cardiac Society, Salzburg, Austria, 2016
- 12) Genetic profiling for patients under dual antiplatelet therapy: does it make sense?" Conference of the European Society of Cardiology, London, UK, 2015
- 13) "When do we need platelet function testing", Intensive course in haemostaseology, Vienna, Austria, 2015
- 14) "Pre-treatment with P2Y12 receptors inhibitors in ACS", Seminars in emergency medicine, Vienna, Austria, 2015
- 15) "Optimal duration of antiplatelet therapy", Seminars for cardiologists of tomorrow, Salzburg, Austria, 2015
- 16) "Assessment of clinical efficacy of antiplatelet agents in patients with acute coronary syndrome", 59th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Düsseldorf, Germany 2015
- 17) "Pheno- and genotyping for prediction of antiplatelet drug safety and efficacy", Annual Conference of the Society of Cardiology, Patras, Greece, 2015
- 18) "6-month antiplatelet treatment is sufficient-contr", Conference of the Austrian Cardiac Society, Salzburg, Austria, 2015
- 19) "Pre-treatment with antiplatelet agents in NSTEMI-contr", Advisory Board Meeting, Vienna, Austria, 2015
- 20) "Monitoring of antiplatelet agents", 1st Annual Congress of the European Society of Vascular Medicine, Potsdam, Germany, 2015
- 21) Platelet function testing and genetic profiling - Update 2014" Seminars in Cardiology, Vienna, Austria, 2014
- 22) "Cardiac health for hemophilia patients", Annual Meeting of the Society of Hemophilia, Salzburg, Austria 2014
- 23) "Indications for platelet function testing", Course in Haemostaseology, Vienna, Austria, 2014
- 24) "Acute coronary syndrome: new aspects regarding antiplatelet therapy", Conference of Emergency Medicine, Vienna, Austria 2014
- 25) "How to improve the concept of individualized antiplatelet therapy – is an algorithm the answer?" Conference on coronary syndromes – questions and answers, Bydgoszcz, Poland 2014
- 26) "Individualized Therapy - are guidelines written for the patients or for the diseases", Conference of the Austrian Cardiac Society, Salzburg, Austria, 2014
- 27) "Management of patients with an ACS treated with a direct oral anticoagulant – what does the guidelines say?", Conference of the Austrian Cardiac Society, Salzburg, Austria, 2014

- 28) "Why have studies of personalized antiplatelet therapy failed so far?", 11th InterCEPT, Milan, Italy, 2014
- 29) "Platelet Function Testing and Genetic Profiling in Clinical Practice: Status Quo", 58th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Vienna, Austria 2014
- 30) "Anticoagulation and physical training", Conference on Rehabilitation Medicine, Vienna, Austria 2013
- 31) "Platelet function testing", Course in Haemostaseology, Vienna, Austria, 2013
- 32) "Platelet inhibition in patients with acute coronary syndromes", Seminars in Emergency Medicine, Vienna, Austria 2013
- 33) "ESC 2013 – Update", Seminars in Cardiology, Vienna, Austria 2013
- 34) "Non-ST-elevation myocardial infarction: pathophysiology, diagnosis and treatment", ACS Meeting, St. Ruprecht an der Raab, Austria, 2013
- 35) "Patients treated with vitamin K antagonist presenting with an acute coronary syndrome: an indication for double or triple antithrombotic therapy?", Conference of the Austrian Society of Cardiology, Salzburg, Austria, 2013
- 36) "Clinical pharmacology and clinical profile of novel platelet inhibitors with a special considerations in patients with diabetes mellitus", Journal Club in Endocrinology, Vienna, Austria 2013
- 37) "Pathophysiology of platelets in patients with diabetes mellitus", 57th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Munich, Germany, 2013
- 38) "For which indications remains clopidogrel as a first choice therapy?", Cardiology Conference, Innsbruck, Austria, 2013
- 39) "Triple antithrombotic therapy" Seminars in Cardiology, Vienna, Austria 2012
- 40) "Personalized antiplatelet therapy", Meeting of the Working Group of Interventional Cardiology of the Austrian Society of Cardiology, Linz, Austria 2012
- 41) "Antithrombotic management of atrial fibrillation in PCI patients", Conference of the International College of Angiology, Innsbruck, Austria, 2012
- 42) "Clinical pharmacology of novel P2Y₁₂ inhibitors", Conference of the German Society for Experimental and Clinical Pharmacology and Toxicology, Dresden, Germany, 2012
- 43) "Balancing between bleeding and thrombotic events: therapeutic window for ADP inhibitors", Conference: Advances in Antiplatelet Therapy, Torun, Poland
- 44) "Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study" Press conference of the European Society of Cardiology, Munich, Germany, 2012
- 45) "Pharmacology of novel platelet inhibitors: considerations for clinical practice" Conference of the Austrian Cardiac Society, Salzburg, Austria, 2012
- 46) "Individualized Antiplatelet Therapy - Fact of Fiction?", Forum in pharmacotherapy, Vienna, Austria 2012
- 47) "Novel platelet inhibitors: therapy start, antidote, bridging and interaction", Conference in Cardiology, Innsbruck, Austria 2012
- 48) "New platelet inhibitors in the treatment of acute coronary syndrome", Seminars in Cardiology, Vienna, Austria 2012
- 49) "On the trail of willow bark extract: What connects aspirin with pop stars", public lecture during "The long night of science", Vienna, Austria 2012
- 50) "Proton pump inhibitors: good for the stomach, bad for the heart", Conference of the Austrian Society of Internal Medicine, Innsbruck, Austria, 2011
- 51) "Relevant drug interactions with platelet aggregation inhibitors", Seminar in Cardiology, Wels, Austria 2011
- 52) "Multiple Electrode Aggregometry: scientific experiences", Multiplate Round Table Meeting, Munich, Germany 2011
- 53) "Novel targets for platelet inhibition to prevent stent thrombosis", CardioWind, Heigerloch, Germany, 2011
- 54) "Phenotyping versus genotyping for prediction of antiplatelet drug efficacy and safety", Conference: Presence and future of antiplatelet therapy; Runowo Krajenskie, Poland 2011
- 55) "Primary prevention in cardiology" at the "Feel good day- meeting for haemophilia patients", Vienna, Austria 2011
- 56) "Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel" Press conference of the European Society of Cardiology, Stockholm, Sweden, 2010
- 57) "Drug-drug interactions in clopidogrel treatment", Masterclass, Vienna 2010
- 58) "Medical research in human and animal: risks, ethics and media. The viewpoint of a medical doctor and scientist", SciCom, Vienna, Austria 2010
- 59) "Stent thrombosis: antiplatelet drug efficacy and role of platelet function testing" International Conference on Platelets and Acute Coronary Syndrome, Torun, Poland, 2010

- 60) "Indications for antiplatelet therapy: primary and secondary prevention", Conference of the Austrian Cardiac Society, Salzburg, Austria, 2009
- 61) "Drug-drug interactions involving clopidogrel", International Conference on Platelets and Atherothrombotic Plaque, Bydgoszcz, Poland, 2009
- 62) "Heart disease: are man and woman different?", public lecture organized by health insurance NÖGKK, Gmünd, Austria, 2008
- 63) "Biological contaminations of swimming pools - health aspects", International Conference of Boleslaw Krzysztofik, Plock, Poland, 2002

Member of scientific committees of conferences:

- 1) Rising Stars in Cardiology, Vienna; Austria 2014
- 2) Rising Stars in Cardiology, Vienna; Austria 2013
- 3) Eurothrombosis, Vienna, 2012
- 4) Conference of the Society of Thrombosis and Haemostasis Research, Vienna, 2014

INTERNATIONAL COLLABORATORS:

Bernard J. Gersh (*Mayo Clinic, College of Medicine, Rochester, USA*); Paul A. Gurbel (*Inova Heart and Vascular Institute, Fairfax, VA, USA*); Freek W.A. Verheugt (*University Hospital Nijmegen, Amsterdam, The Netherlands*); Marie Lordkipanidzé (*Montreal Heart Institute, Canada*); Raffaele De Caterina (*"G. d'Annunzio" University - Chieti-Pescara, Italy*); Philippe Kolh (*University Hospital of Liege, Belgium*); Dietmar Trenk (*Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany*); Karsten Schrör (*Heinrich-Heine-Universität, Düsseldorf, Germany*); Meinrad Gawaz and Tobias Geisler (*Eberhard Karls University, Tübingen, Germany*); Steen D. Kristensen and Erik Grove (*Aarhus University Hospital, Denmark*); Robert F. Storey (*University of Sheffield, UK*); Stephan Krähenbühl (*University Hospital Basel, Switzerland*); Alan D. Michelson (*Harvard Medical School, Boston, MA, USA*); Jacek Kubica, Tomasz Grzybowski and Marek Kozinski (*Collegium Medicum of the Nicolaus Copernicus University, Bydgoszcz, Poland*); Daniel Aradi (*Semmelweis University Budapest, Hungary*); Dirk Sibbing (*Ludwig-Maximilians-University, Munich, Germany*); Anna Komosa and Maciej Lesiak (*Poznan University of Medical Sciences, Poland*); Yahye Merhi (*Montreal Heart Institute, Canada*); Denisa Wagner (*Harvard Medical School, Boston, USA*); Eliano Navarese (*Heinrich-Heine-University, Düsseldorf, Germany*); Marek Postula (*Medical University of Warsaw, Warsaw, Poland*); Diana Gorog (*Imperial College, London, UK*); Ingo Ahrens (*University Heart Center Freiburg, Freiburg, Germany*); International Clopidogrel Pharmacogenomics Consortium.

EDITORIAL BOARD MEMBER:

- 1) Austrian Journal of Cardiology,
- 2) Folia Cardiologica
- 3) Advances in Interventional Cardiology

BIBLIOGRAPHY

SUMMARY	sum (n)	Source
total publications (without meeting abstracts)	97	
publications as a first author	59	
peer-reviewed publications: total / as a first author / as a senior author	73/35/4	PubMed
original research articles: total / as a first author	55/26	PubMed
review articles: English / German	18/25	
book chapters / monographs / editorials / consensus documents	3/1/1/1	
Citations	2603	Scopus
	3546	Google Scholar
sum of impact points	392	JCR- ISI
h-index	25	Scopus
	29	Google Scholar
i10-index	56	Google Scholar

15 most relevant articles:	times cited	comment
1. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. <i>Am Heart J</i> 2009; 157 (1):148.e1-148.e5.	349	- Best Poster Award, GTH 2009 - cited by FDA 2010
2. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. <i>J Am Coll Cardiol</i> 2008; 52 (19):1557-63.	221	- Best Clinical Paper Award, ÖKG 2009
3. Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. <i>J Thromb Haemost</i> 2010; 8 (12):2624-41.	114	
4. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay. <i>J Thromb Haemost</i> 2010; 8 (2):351-9.	94	
5. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. <i>J Thromb Haemost</i> 2012; 10 (4):529-42.	57	- Second Best Clinical Paper Award, ÖKG 2011
6. Siller-Matula JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, Pendergrast PS, Chung JK, Tian X, Schaub RG, Jilma B. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. <i>Arterioscler Thromb Vasc Biol</i> 2012; 32 (4):902-9.	25	- Karl Link Early Career Investigator Award, AHA 2013 - Werner Klein Award, ÖKG 2013
7. Siller-Matula JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H, Jilma B. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a Systematic Review and Meta-analysis. <i>Heart</i> 2011; 97 (2):98-105.	39	- cited by ACCF/AHA/SCAI Guidelines for PCI 2011
8. Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, De Servi S, Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. <i>J Thromb Haemost</i> 2011; 9 (10):1902-15.	44	- cited by ESC Guidelines for STEMI, 2012
9. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeczek-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. <i>Int J Cardiol</i> 2013; 167 (5):2018-23.	67	- Best Poster Award, Eurothrombosis 2012
10. Siller-Matula JM. Hemorrhagic complications associated with aspirin: An underestimated hazard in clinical practice? <i>JAMA</i> . 2012; 307 :2318-2320	17	- Invited editorial
11. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K, Epa. Response variability to P2Y12 receptor inhibitors: Expectations and reality. <i>JACC Cardiovasc Interv</i> . 2013; 6 :1111-1128	51	
12. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled impression trial. <i>Eur Heart J</i> . 2016; 37 :245-252	35	
13. Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K, European Platelet Academy. How to improve the concept of individualised antiplatelet therapy with p2y12 receptor inhibitors--is an algorithm the answer? <i>Thromb Haemost</i> . 2015; 113 :37-52	16	
14. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freyhofner MK, Ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on p2y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>Eur Heart J</i> . 2015	63	

15. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J , Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. <i>J Am Coll Cardiol</i> . 2013;62:2261-2273	345	- Consensus Document
--	-----	----------------------

All peer reviewed publications:

1. Schoergenhofer C, Hobl EL, Staudinger T, Speidl WS, Heinz G, **Siller-Matula J**, Zauner C, Reiter B, Kubica J, Jilma B. Prasugrel in critically ill patients. *Thromb Haemost*. 2017;117:in press
2. Komosa A, Rzymiski P, Perek B, Ropacka-Lesiak M, Lesiak M, **Siller-Matula JM**, Poniedzialek B. Platelets redox balance assessment: Current evidence and methodological considerations. *Vascular pharmacology*. 2017:in press
3. Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, **Siller-Matula JM**. Advocating cardiovascular precision medicine with p2y12 receptor inhibitors. *European heart journal. Cardiovascular pharmacotherapy*. 2017:in press
4. Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozd J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, **Siller-Matula JM**, Witkowski A, Kuliczowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M, Wojcik J. Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts' standpoint. *Kardiol Pol*. 2017;75:399-408
5. Niezgoda P, Sikora J, Baranska M, Sikora A, Buszko K, Sieminska E, Marszall MP, **Siller-Matula JM**, Jilma B, Alexopoulos D, Fabiszak T, Kubica J. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. *Thromb Haemost*. 2017;117:718-726
6. Navarese EP, Kolodziejczak M, Winter MP, Alimohammadi A, Lang IM, Buffon A, Lip GY, **Siller-Matula JM**. Association of pcsk9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The pcsk9-react study. *Int J Cardiol*. 2017;227:644-649
7. **Siller-Matula JM**, Specht S, Kubica J, Alexopoulos D, De Caterina R, Hobl EL, Jilma B, Christ G, Lang IM. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in stemi patients. *Br J Clin Pharmacol*. 2016;82:1343-1350
8. **Siller-Matula JM**, Akca B, Neunteufl T, Maurer G, Lang IM, Kreiner G, Berger R, Delle-Karth G. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. *Platelets*. 2016;27:373-377
9. Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, **Siller-Matula JM**, Dabrowska A, Fabiszak T, Kozinski M, Gurbel PA. Impact of morphine on antiplatelet effects of oral p2y12 receptor inhibitors. *Int J Cardiol*. 2016;215:201-208
10. **Siller-Matula JM**, Hintermeier A, Kastner J, Kreiner G, Maurer G, Kratochwil C, Lang IM, Delle-Karth G. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. *Vascular pharmacology*. 2016;79:6-10
11. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, **Siller-Matula JM**, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled impression trial. *Eur Heart J*. 2016;37:245-252
12. Komosa A, **Siller-Matula JM**, Lesiak M, Michalak M, Kowal J, Maczynski M, Siniawski A, Mularek-Kubzdela T, Wisniewski S, Grajek S. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. *Thromb Res*. 2016;138:49-54
13. Winter MP, Kozinski M, Kubica J, Aradi D, **Siller-Matula JM**. Personalized antiplatelet therapy with p2y12 receptor inhibitors: Benefits and pitfalls. *Postepy w kardiologii interwencyjnej = Advances in interventional cardiology*. 2015;11:259-280
14. **Siller-Matula JM**, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K, European Platelet A. How to improve the concept of individualised antiplatelet therapy with p2y12 receptor inhibitors--is an algorithm the answer? *Thromb Haemost*. 2015;113:37-52

15. **Siller-Matula JM**, Petre A, Delle-Karth G, Huber K, Ay C, Lordkipanidze M, De Caterina R, Kolh P, Mahla E, Gersh BJ. Impact of preoperative use of p2y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. *European heart journal. Acute cardiovascular care*. 2015;DOI: 10.1177/2048872615585516
16. **Siller-Matula JM**, Gruber C, Francesconi M, Dechant C, Jilma B, Delle-Karth G, Grohs K, Podczeck-Schweighofer A, Christ G. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. *Clin Sci (Lond)*. 2015;128:121-130
17. Ozsoy M, Klatte T, Wiener H, **Siller-Matula J**, Schmidbauer J. Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section. *Urologic oncology*. 2015;33:67 e25-69
18. Droppa M, Tschernow D, Muller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, **Siller-Matula JM**, Gawaz M, Geisler T. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (predict-stable). *PLoS One*. 2015;10:e0121620
19. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, **Siller-Matula JM**, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on p2y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J*. 2015;in press
20. **Siller-Matula JM**, Trenk D, Krahenbuhl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with p2y12 receptor inhibitors. *J Thromb Haemost*. 2014;12:2-13
21. **Siller-Matula JM**, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J, Jilma B. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. *PLoS One*. 2014;9:e102701
22. **Siller-Matula JM**, Delle Karth G. [dual platelet inhibitors in intensive care units.]. *Medizinische Klinik, Intensivmedizin und Notfallmedizin*. 2014:1-8
23. **Siller-Matula JM**, Arbesu I, Jilma B, Maurer G, Lang IM, Mannhalter C. Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention. *Thromb Haemost*. 2014;111:1060-1066
24. Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, **Siller-Matula JM**, Jeong YH, Fabiszak T, Andruszkiewicz A, Gurbel PA. Cangrelor: An emerging therapeutic option for patients with coronary artery disease. *Curr Med Res Opin*. 2014;doi: 10.1185/03007995.2014.880050.
25. Kubica A, Kasprzak A, **Siller-Matula J**, Kozinski M, Pio Navarese E, Obonska K, Andruszkiewicz A, Sztuba B, Fabiszak T, Swiatkiewicz I, Paciorek P, Kubica J. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. *Eur J Pharmacol*. 2014;742:47-54
26. Kozinski M, Obonska K, Stankowska K, Navarese EP, Fabiszak T, Stolarek W, Kasprzak M, **Siller-Matula JM**, Rosc D, Kubica J, De Servi S. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. *Cardiol J*. 2014;doi: 10.5603/CJ.a2014.0026.:in press
27. Komosa A, **Siller-Matula JM**, Kowal J, Lesiak M, Siniawski A, Maczynski M, Michalak M, Mularek-Kubzdela T, Grajek S. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-egitromb. *Platelets*. 2014;in press
28. Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, Pirker-Kees A, **Siller-Matula JM**. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: A systematic review and meta-analysis. *Stroke*. 2014;45:492-503
29. Christ G, **Siller-Matula JM**, Francesconi M, Dechant C, Grohs K, Podczeck-Schweighofer A. Individualising dual antiplatelet therapy after percutaneous coronary intervention: The ideal-pci registry. *BMJ Open*. 2014;4:e005781
30. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, **Siller-Matula J**, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. *J Am Coll Cardiol*. 2013;62:2261-2273
31. **Siller-Matula JM**, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K, Epa. Response variability to p2y12 receptor inhibitors: Expectations and reality. *JACC Cardiovasc Interv*. 2013;6:1111-1128

32. **Siller-Matula** JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? *Thromb Haemost.* 2013;110:628-631
33. **Siller-Matula** JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The madonna study. *Int J Cardiol.* 2013;167:2018-2023
34. **Siller-Matula** JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, Tolios A, Drucker C, Jilma B. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. *Int J Cardiol.* 2013;167:430-435
35. Christ G, Hafner T, **Siller-Matula** JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A. Platelet inhibition by abciximab bolus-only administration and oral adp receptor antagonist loading in acute coronary syndrome patients: The blocking and bridging strategy. *Thromb Res.* 2013;132:e36-e41
36. Steinhauser G, Adlassnig W, Risch JA, Anderlini S, Arguriou P, Armendariz AZ, Bains W, Baker C, Barnes M, Barnett J, Baumgartner M, Baumgartner T, Bendall CA, Bender YS, **Siller-Matula** J, et al. Peer review versus editorial review and their role in innovative science. *Theor Med Bioeth.* 2012;33:359-376
37. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, **Siller-Matula** JM, Jilma B. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: A randomized controlled trial. *Clin Sci (Lond).* 2012;123:591-600
38. **Siller-Matula** JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nobauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E, Jilma B. Continuous thrombin infusion leads to a bleeding phenotype in sheep. *Thromb Res.* 2012;130:226-236
39. **Siller-Matula** JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, Pendergrast PS, Chung JK, Tian X, Schaub RG, Jilma B. Arc15105 is a potent antagonist of von willebrand factor mediated platelet activation and adhesion. *Arterioscler Thromb Vasc Biol.* 2012;32:902-909
40. **Siller-Matula** JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Phenotyping vs. Genotyping for prediction of clopidogrel efficacy and safety: The pegasus-pci study. *J Thromb Haemost.* 2012;10:529-542
41. **Siller-Matula** JM. Hemorrhagic complications associated with aspirin: An underestimated hazard in clinical practice? *Jama.* 2012;307:2318-2320
42. Schror K, **Siller-Matula** JM, Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. *Fundam Clin Pharmacol.* 2012;26:39-46
43. Heinisch BB, Vcelar B, Kapiotis S, Blann A, Wolzt M, **Siller-Matula** JM, Jilma B. The effect of erythropoietin on platelet and endothelial activation markers: A prospective trial in healthy volunteers. *Platelets.* 2012;23:352-358
44. Grzesk G, Kozinski M, Navarese EP, Krzyzanowski M, Grzesk E, Kubica A, **Siller-Matula** JM, Castriota F, Kubica J. Ticagrelor, but not clopidogrel and prasugrel, prevents adp-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. *Thromb Res.* 2012;130:65-69
45. Yukhanyan L, Freynhofer MK, **Siller-Matula** J, Schror K, Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. *Thromb Haemost.* 2011;105:Suppl 1:S55-59
46. Tentzeris I, **Siller-Matula** J, Farhan S, Jarai R, Wojta J, Huber K. Platelet function variability and non-genetic causes. *Thromb Haemost.* 2011;105:Suppl 1:S60-66
47. Spiel AO, Bartko J, Schwameis M, Firbas C, **Siller-Matula** J, Schuetz M, Weigl M, Jilma B. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial. *Thromb Haemost.* 2011;105:655-662
48. **Siller-Matula** JM, Schwameis M, Blann A, Mannhalter C, Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. *Thromb Haemost.* 2011;106:1020-1033
49. **Siller-Matula** JM, Jilma B. Response to letter by lin et al. "Clopidogrel loading dose in patients undergoing elective percutaneous coronary intervention". *Heart.* 2011;97:2011
50. **Siller-Matula** JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H, Jilma B. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. *Heart.* 2011;97:98-105
51. **Siller-Matula** JM, Delle-Karth G. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding. *Evid Based Med.* 2011;16:144-145

52. **Siller-Matula JM.** Thrombin as a multifunctional enzyme: Establishing experimental models to study thrombin effects. *Südwestdeutscher Verlag für Hochschulschriften.* 2011;1-96
53. Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, **Siller-Matula JM**, Sukiennik A, De Servi S, Kubica J. Low-molecular-weight heparins vs. Unfractionated heparin in the setting of percutaneous coronary intervention for st-elevation myocardial infarction: A meta-analysis. *J Thromb Haemost.* 2011;9:1902-1915
54. Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, **Siller-Matula JM**, Rosc D, Kubica J. Diurnal variation in platelet inhibition by clopidogrel. *Platelets.* 2011;22:579-587
55. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, **Siller-Matula J**, Gilbert JC, Knobl P. Inhibition of von willebrand factor by arc1779 in patients with acute thrombotic thrombocytopenic purpura. *Thromb Haemost.* 2011;105:545-552
56. Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, **Siller-Matula J**, Huber K. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. *Thromb Haemost.* 2010;104:1211-1218
57. Spiel AO, **Siller-Matula J**, Firbas C, Leitner JM, Russmueller G, Jilma B. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans. *Platelets.* 2010;21:464-469
58. **Siller-Matula JM**, Tentzeris I, Vogel B, Schacherl S, Jarai R, Geppert A, Unger G, Huber K. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points. *Clin Res Cardiol.* 2010;99:645-650
59. **Siller-Matula JM**, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis. *J Thromb Haemost.* 2010;8:2624-2641
60. **Siller-Matula JM**, Jilma B. Ticagrelor: From discovery to phase iii clinical trial. *Future Cardiology.* 2010;6:753-764
61. **Siller-Matula JM**, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasp assay. *J Thromb Haemost.* 2010;8:351-359
62. **Siller-Matula JM**, Bayer G, Bergmeister H, Quehenberger P, Petzelbauer P, Friedl P, Mesteri I, Jilma B. An experimental model to study isolated effects of thrombin in vivo. *Thromb Res.* 2010;126:454-461
63. Mayr FB, Knobl P, Jilma B, **Siller-Matula JM**, Wagner PG, Schaub RG, Gilbert JC, Jilma-Stohlawetz P. The aptamer arc1779 blocks von willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. *Transfusion.* 2010;50:1079-1087
64. Firbas C, **Siller-Matula JM**, Jilma B. Targeting von willebrand factor and platelet glycoprotein ib receptor. *Expert Rev Cardiovasc Ther.* 2010;8:1689-1701
65. **Siller-Matula JM**, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. *Am Heart J.* 2009;157:148.e141-148.e145
66. **Siller-Matula JM**, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease. *British Journal of Pharmacology.* 2009;159:502-517
67. **Siller-Matula JM**, Jilma B. Response to letter by tho: "Do the association of cytochrome p450 interacting drugs, influence clopidogrel efficacy?". *Am Heart J.* 2009;158:e9
68. **Siller-Matula JM**, Jilma B. Response to letter by van werkum: "Proton pump inhibitors and clopidogrel: A difficult dilemma". *Am Heart J.* 2009;157:e45
69. **Siller-Matula JM**, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. *Thromb Res.* 2009;123:874-880
70. **Siller-Matula JM**, Gouya G, Wolzt M, Jilma B. Cross validation of the multiple electrode aggregometry. A prospective trial in healthy volunteers. *Thromb Haemost.* 2009;102:397-403
71. Kasprzak M, Kozinski M, Bielis L, Boinska J, Plazuk W, Marciniak A, Budzynski J, **Siller-Matula J**, Rosc D, Kubica J. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. *Cardiol J.* 2009;16:535-544
72. **Siller-Matula JM**, Plasenzotti R, Spiel A, Quehenberger P, Jilma B. Interspecies differences in coagulation profile. *Thromb Haemost.* 2008;100:397-404
73. **Siller-Matula JM**, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. *Platelets.* 2008;19:551-554

74. **Siller-Matula JM**, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. *J Am Coll Cardiol*. 2008;52:1557-1563
75. **Siller-Matula JM**, Jilma B. Strain differences in toxic effects of long-lasting isoflurane anaesthesia between wistar rats and sprague dawley rats. *Food Chem Toxicol*. 2008;46:3550-3552
76. **Siller-Matula J**, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. *Thromb Haemost*. 2007;97:385-393

Review articles and book chapters in German language:

1. Winter MP, **Siller-Matula J**. Was empfehlen die Guidelines? NSTEMI – welche Antiplättchentherapie für wen? *Jatros: Kardiologie & Gefäßmedizin* 2016;3:62-64.
2. **Siller-Matula JM**. Aktuelles: Vorbehandlung mit P2Y12-Rezeptorinhibitoren bei Patienten mit NSTEMI-ACS. *J Kardiologie* 2015;22:7-8.
3. Specht S, **Siller-Matula JM**. NSTEMI-ACS bei VHF: Management bei vorbestehender Therapie mit DOAK. *Jatros: Kardiologie & Gefäßmedizin* 2014;3:24-25.
4. **Siller-Matula J**. Akutes Koronarsyndrom: Entscheidungskriterien für die Wahl des Plättchenhemmers. *Arzt und Praxis* 2014;68:18-20.
5. **Siller-Matula JM**. Prasugrel: Management des ACS- Patienten mit Diabetes. *Universum Innere Medizin* 2013;08:32-33.
6. **Siller-Matula JM**. Aktuelles: Management des Diabetes-ACS-Patienten mit Prasugrel. *J Hyperton* 2013;17:168-9.
7. **Siller-Matula JM**. Nutzen-Risiko-Profil von Aspirin in der Primär- und Sekundärprävention. *J Hyperton* 2013;17:117-8.
8. **Siller-Matula J**, Huber K. Klinische Studien mit neuen Plättchenfunktionshemmern in K. Schrör & W. Kirch (eds) *Pharmakologie und Klinik neuer Antiplättchensubstanzen*. Schattauer 2013:23-46.
9. Huber K, **Siller-Matula J**, Schrör K. Antiplättchentherapie -aktueller Stand und zukünftige Entwicklungen in K. Schrör & W. Kirch (eds) *Pharmakologie und Klinik neuer Antiplättchensubstanzen*. Schattauer 2013:155-164.
10. Akca B, **Siller-Matula JM**. Platelet Function Testing: Expectations and Reality. *J Kardiologie* 2013;20:160–7.
11. **Siller-Matula JM**. Das Ansprechen auf die Plättchenhemmung messen: Individualisierte Anti-Plättchen-Therapie. *Universum Innere Medizin* 2012;09:45-46.
12. **Siller-Matula JM**. Individualisierte Anti-Plättchen-Therapie. *Universum Innere Medizin* 2012;8:32-33.
13. **Siller-Matula JM**. Der Thrombozyt beim ACS. in Alber H. (eds) *Thrombozytenhemmung beim akuten Koronarsyndrom*. Unimed Verlag 2012:31-40.
14. **Siller-Matula JM**. Thrombozytenaggregationshemmung: Nicht alle Patienten sind gleich. *Universum Innere Medizin* 2012;7:18.
15. **Siller-Matula JM**. Protonenpumpenhemmer 2011: Gut für den Magen, schlecht für das Herz? *Universum Innere Medizin* 2011;8:10.
16. Jilma B, **Siller-Matula JM**. Ticagrelor zur Behandlung des akuten Koronarsyndroms. *Pharmainformation* 2011;26:2.
17. **Siller-Matula JM**, Firbas C, Jilma B. Plättchenaggregationshemmer-Kontrolle der Wirkung: wie und bei wem? *Universum Innere Medizin* 2010;08:66-67.
18. **Siller-Matula JM**. Gleichzeitige Behandlung mit Clopidogrel und PPI Auswirkungen auf die klinische Prognose. *Jatros* 2010;4:48-49.
19. Jilma B, **Siller-Matula JM**. Behandlung kardiovaskulärer Erkrankungen mit derzeit verfügbaren oralen Plättchenhemmern (Acetylsalicylsäure, Clopidogrel, Prasugrel). *Pharmainformation* 2010;25:3-5.
20. **Siller-Matula JM**. Plättcheninhibitoren in der Prävention der KHK. *Leading Opinions* 2009;4:9-11.
21. **Siller-Matula JM**. Indikationen für Plättchen-Inhibitoren in der Primär- und Sekundärprävention. *Wiener Medizinische Wochenschrift* 2009;7:23-24.
22. **Siller-Matula J**. Koronare Herzkrankheit: Plättcheninhibitoren in der Prävention der KHK. *Jatros* 2009;5:12-15.
23. Höchtl T, Schrör K, **Siller-Matula JM**, Freyhof M, Wojta J, Huber K. Prasugrel, ein neues Thienopyridin. *Kardiologie Journal* 2009;16:5-6.
24. Christ G, **Siller-Matula J**, Huber K. Antithrombotische Behandlung nach einer Koronarstent-Implantation. *Universum Innere Medizin* 2009;07:76-78.
25. **Siller-Matula JM**, Jilma B. Aspirin - Resistenz. *Universum Innere Medizin* 2008;04:20-21.